Olakanmi Ololade
Grinnell College, USA.
Penn Bioeth J. 2006 Spring;2(2):38-41.
There are many potential benefits that xenotransplantation (cross-species transplantation) might afford us, but there are also many weighty biological hurdles which must be surmounted if this procedure is ever to become a clinical reality. Many of these biological concerns are being addressed by specific and novel therapies; however, we must still determine the point at which xenotransplantation could be considered safe enough for clinical implementation. Many members of the scientific community believe that we should strive to make xenotransplantation products as safe and effective as possible, whereas others argue that we should not need to optimize the safety and efficaciousness of xenotransplantation products for them to be deemed acceptable for human use. In this paper I take the latter position, I argue that "the scientific community should move from the paradigm of...trying to indicate to society optimal solutions to that of...trying to help society in finding 'satisficing' solutions" which, although not necessarily optimal, are, nevertheless, good enough (Giampietro, 2002, p. 466).
异种移植(跨物种移植)可能会给我们带来许多潜在益处,但如果该程序要成为临床现实,还存在许多重大的生物学障碍必须克服。其中许多生物学问题正通过特定的新颖疗法来解决;然而,我们仍必须确定在何种程度上异种移植可被认为足够安全以用于临床实施。科学界的许多成员认为,我们应努力使异种移植产品尽可能安全有效,而另一些人则认为,对于异种移植产品被认为可用于人类,我们无需优化其安全性和有效性。在本文中,我持后一种观点,我认为“科学界应从……试图向社会指出最优解决方案的范式,转向……试图帮助社会找到‘满意’解决方案的范式”,这些解决方案虽然不一定是最优的,但仍然足够好(詹皮耶特罗,2002年,第466页)。